|
|
|
|
Given the mechanism of action of intravenous recombinant tissue plasminogen activator, clinical studies could include agents with a fast onset of action, such as prothrombin complex concentrate, recombinant factor Vlla, and ?-aminocaproic acid, as potential therapeutic options. |
|